Prescription of statins at discharge and one ‐year risk of major clinical outcomes among ACS patients with extremely low LDL‐c in CPACS studies

Clinical Cardiology,Volume 0, Issue ja, -Not available-.
Source: Clinical Cardiology - Category: Cardiology Authors: Source Type: research

Related Links:

U.S. regulators have approved a new type of cholesterol-lowering drug aimed at millions of people who don't get enough help from widely used statin pills like Lipitor and Crestor
Source: ABC News: Health - Category: Consumer Health News Tags: Health Source Type: news
The US Food and Drug Administration on Friday approved a drug to treat high cholesterol that works differently than statins, according to Esperion Therapeutics, the company that makes the drug.
Source: CNN.com - Health - Category: Consumer Health News Source Type: news
U.S. regulators have approved a new type of cholesterol-lowering drug aimed at millions of people who don't get enough help from widely used statin pills like Lipitor and Crestor
Source: ABC News: Health - Category: Consumer Health News Tags: Health Source Type: news
Esperion Therapeutics Inc said on Friday that U.S. health regulators approved its cholesterol-lowering drug, making it the first non-statin treatment to be cleared for sale in the country in nearly 20 years.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
The non-statin drug bempedoic acid was granted approval for adults with familial hypercholesterolemia or established atherosclerotic CVD.FDA Approvals
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Alert Source Type: news
Bempedoic acid will provide patients and doctors with another tool to fight heart disease, the number one cause of death worldwide.
Source: Washington Post: To Your Health - Category: Consumer Health News Authors: Source Type: news
Authors: Ponticelli C, Arnaboldi L, Moroni G, Corsini A Abstract Introduction: Lipid disorders are frequent after kidney transplantation (KT) and KT recipients are considered at high- or very-high cardiovascular risk. Among many concurring factors, a major role is played by immunosuppressants.Areas covered: General measures to manage lipid disorders first include physical activity and diet counseling. Modulating the doses of immunosuppressants also improves dyslipidemia. When lipid-lowering drugs are necessary to control elevated plasma cholesterol and/or triglycerides, statins are the cornerstone for managing hype...
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research
ConclusionAdequate treatment with statins after stroke may lower the risk of PSE.
Source: Neurological Sciences - Category: Neurology Source Type: research
ConclusionsIn Chinese subjects, alirocumab 75, 150, and 300  mg was safe and well-tolerated. Pharmacokinetic/pharmacodynamic parameters, including clinically meaningful reductions in LDL-C and other lipids/lipoproteins, were consistent with data from Japanese and Western populations.Clinicaltrials.gov identifier: NCT02979015.
Source: American Journal of Cardiovascular Drugs - Category: Cardiology Source Type: research
In this study, we aimed at investigating the association between statin pretreatment and poststroke myocardial injury. Methods: Six hundred seventy-one patients diagnosed as acute ischemic stroke were enrolled. According to the histories of statin pretreatment before stroke, patients were categorized into nonstatin (n  = 474) and statin groups (n = 197), with the latter further divided into low-dosage, standard-dosage, and high-dosage subgroups according the dosages of statins.
Source: Journal of Stroke and Cerebrovascular Diseases - Category: Neurology Authors: Source Type: research
More News: Cardiology | Cholesterol | Heart | Statin Therapy | Study